Suchen

New Rapid-acting Antidepressants (eBook)

ISBN: 978-3-030-79790-4
GTIN: 9783030797904
Einband: PDF
Verfügbarkeit: Download, sofort verfügbar (Link per E-Mail)
Unsere Staffelpreise:
Menge
10+
20+
50+
Preis
CHF 191.25
CHF 185.95
CHF 180.65
CHF 212.50
decrease increase
This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists.  There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy.  The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area.  In this volume, a variety of novel pharmaceutical treatments are examined.  This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.

Discusses new candidate for rapid-acting antidepressants

Provides information for those who work in the field of CNS drugs

Ideal for pharmacologists, psychiatrists, and those who want to learnabout CNS drugs at the graduate level

This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists.  There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy.  The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area.  In this volume, a variety of novel pharmaceutical treatments are examined.  This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.

Discusses new candidate for rapid-acting antidepressants

Provides information for those who work in the field of CNS drugs

Ideal for pharmacologists, psychiatrists, and those who want to learnabout CNS drugs at the graduate level

*
*
*
*
AutorHashimoto, Kenji (Hrsg.) / Manto, Mario (Hrsg.)
VerlagSpringer International Publishing
EinbandPDF
Erscheinungsjahr2021
Seitenangabe149 S.
AusgabekennzeichenEnglisch
AbbildungenVII, 149 p. 14 illus., 9 illus. in color.
Masse3'764 KB
PlattformPDF
ReiheContemporary Clinical Neuroscience
ISBN978-3-030-79790-4

Über den Autor Kenji (Hrsg.) Hashimoto

First Name - Kenji Last Name - Hashimoto Institution - Chiba University Center for Forensic Mental Health Department - Division of Clinical Neuroscience City - Chiba 260-8670 State - Chiba Country - Japan Email - hashimoto@faculty.chiba-u.jp Kenji Hashimoto, PhD Chiba University, Chiba, Japan Dr. Hashimoto is a professor and vice-director of Chiba University Center for Forensic Mental Health from 2005. Dr. Hashimoto graduated from Faculty of Pharmaceutical Sciences at Kyushu University, and received PhD. After Dr. Hashimoto worked at Fukuyama University, National Institutes of Health (NIH)/National Institute of Drug Addiction (NIDA)(Baltimore, MD, USA) and Pharmaceutical company, he moved at Chiba University Graduate School of Medicine from 2001. Dr. Hashimoto works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto published more than 550articles in PubMed listed publications. Dr. Hashimoto focus on the molecular and cellular mechanisms of ketamine's antidepressant actions.

Weitere Titel von Kenji (Hrsg.) Hashimoto

Alle Bände der Reihe "Contemporary Clinical Neuroscience"

Filters
Sort
display